Marinus Pharmaceuticals Statistics
Total Valuation
MRNS has a market cap or net worth of $78.00 million. The enterprise value is $75.38 million.
| Market Cap | 78.00M |
| Enterprise Value | 75.38M |
Important Dates
The last earnings date was Wednesday, May 8, 2024, before market open.
| Earnings Date | May 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
MRNS has 54.93 million shares outstanding. The number of shares has increased by 9.82% in one year.
| Shares Outstanding | 54.93M |
| Shares Change (YoY) | +9.82% |
| Shares Change (QoQ) | +0.23% |
| Owned by Insiders (%) | 0.97% |
| Owned by Institutions (%) | 104.50% |
| Float | 37.75M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.76 |
| Forward PS | 1.79 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.66 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.07
| Current Ratio | 3.07 |
| Quick Ratio | 2.73 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.59 |
Financial Efficiency
Return on equity (ROE) is -518.10% and return on invested capital (ROIC) is -142.63%.
| Return on Equity (ROE) | -518.10% |
| Return on Assets (ROA) | -81.90% |
| Return on Capital (ROIC) | -142.63% |
| Revenue Per Employee | $171,442 |
| Profits Per Employee | -$880,873 |
| Employee Count | 165 |
| Asset Turnover | 0.16 |
| Inventory Turnover | 0.85 |
Taxes
| Income Tax | -1.54M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -80.03% in the last 52 weeks. The beta is 1.14, so MRNS's price volatility has been higher than the market average.
| Beta (1Y) | 1.14 |
| 52-Week Price Change | -80.03% |
| 50-Day Moving Average | 3.68 |
| 200-Day Moving Average | 7.11 |
| Relative Strength Index (RSI) | 28.80 |
| Average Volume (30 Days) | 2,154,028 |
Short Selling Information
The latest short interest is 4.89 million, so 8.90% of the outstanding shares have been sold short.
| Short Interest | 4.89M |
| Short Previous Month | 5.00M |
| Short % of Shares Out | 8.90% |
| Short % of Float | 12.94% |
| Short Ratio (days to cover) | 1.07 |
Income Statement
In the last 12 months, MRNS had revenue of $28.29 million and -$145.34 million in losses. Loss per share was -$2.64.
| Revenue | 28.29M |
| Gross Profit | 25.80M |
| Operating Income | -134.34M |
| Pretax Income | -146.88M |
| Net Income | -145.34M |
| EBITDA | -129.08M |
| EBIT | -129.79M |
| Loss Per Share | -$2.64 |
Balance Sheet
The company has $113.25 million in cash and $110.63 million in debt, giving a net cash position of $2.63 million or $0.05 per share.
| Cash & Cash Equivalents | 113.25M |
| Total Debt | 110.63M |
| Net Cash | 2.63M |
| Net Cash Per Share | $0.05 |
| Equity / Book Value | -16.43M |
| Book Value Per Share | -0.30 |
| Working Capital | 88.52M |
Cash Flow
In the last 12 months, operating cash flow was -$113.98 million and capital expenditures -$110,000, giving a free cash flow of -$114.09 million.
| Operating Cash Flow | -113.98M |
| Capital Expenditures | -110,000 |
| Free Cash Flow | -114.09M |
| FCF Per Share | -$2.01 |
Margins
Gross margin is 91.22%, with operating and profit margins of -474.91% and -513.80%.
| Gross Margin | 91.22% |
| Operating Margin | -474.91% |
| Pretax Margin | -519.24% |
| Profit Margin | -513.80% |
| EBITDA Margin | -456.31% |
| EBIT Margin | -458.81% |
| FCF Margin | -403.33% |
Dividends & Yields
MRNS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.82% |
| Shareholder Yield | -9.82% |
| Earnings Yield | -186.33% |
| FCF Yield | -146.27% |
Analyst Forecast
The average price target for MRNS is $11.75, which is 727.47% higher than the current price. The consensus rating is "Buy".
| Price Target | $11.75 |
| Price Target Difference | 727.47% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 62.58% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on September 23, 2020. It was a reverse split with a ratio of 1:4.
| Last Split Date | Sep 23, 2020 |
| Split Type | Reverse |
| Split Ratio | 1:4 |
Scores
MRNS has an Altman Z-Score of -8.06 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.06 |
| Piotroski F-Score | 3 |